Guidelines for Substituting Levothyroxine Brands (including Oroxine)

1. Equivalence and Bioavailability

Levothyroxine (the active hormone T4) and the brand Oroxine contain the identical active ingredient, allowing substitution; however, bioavailability can differ by 20–25 % between preparations, so thyroid‑stimulating hormone (TSH) should be re‑checked 4–8 weeks after any brand change. American College of Endocrinology recommendation. 1
The American Association of Clinical Endocrinologists (AACE) and the American Thyroid Association (ATA) advise maintaining a consistent levothyroxine formulation for each patient to minimize inter‑prescription variability. 2
In vitro dissolution testing demonstrates significant differences among levothyroxine tablets, driven by pH‑dependent release and inactive ingredients; these differences can translate into clinically meaningful variations in bioavailability. AACE guidance. 2
Approximately 70 % of an oral levothyroxine dose is absorbed; absorption is affected by tablet formulation, excipients, and individual gastrointestinal factors. AACE data. 1
Do not assume therapeutic equivalence without verification; even FDA‑approved generics may exhibit bioavailability ranges that produce clinically relevant TSH changes in individual patients. AACE caution. 2

After any levothyroxine brand switch, serum TSH must be measured 4–8 weeks later to confirm that the target range is maintained and to guide dose adjustments. AACE protocol. 1
If TSH lies outside the desired range, adjust the dose in increments of 12.5–25 µg (or the nearest appropriate tablet strength). AACE dosing recommendation. 1
Prescribe the new brand at the same microgram dose the patient was receiving previously; this provides a baseline for subsequent monitoring. AACE prescribing guidance. 2
Once TSH is stable on the new formulation, monitor thyroid function every 6 months initially, then annually. AACE follow‑up schedule. 5

Instruct patients to take levothyroxine on an empty stomach—30–60 minutes before breakfast with a full glass of water—or at bedtime at least 4 hours after the last meal, to optimize absorption. AACE administration advice. [4][1]
Store levothyroxine tablets at 20–25 °C (68–77 °F), protected from light and moisture, as per product labeling. AACE storage recommendation. 1

Pregnant patients who change levothyroxine brands should have TSH checked every 4 weeks during the first half of pregnancy and at least once between 26–32 weeks gestation, because small bioavailability differences can affect fetal neurodevelopment. AACE obstetric guidance. 4

Do not switch levothyroxine brands repeatedly or allow pharmacy‑driven automatic substitutions without an explicit monitoring plan, as this introduces unnecessary variability and risk of under‑ or over‑replacement. AACE safety warning. 2
Do not delay post‑switch TSH monitoring beyond 8 weeks; prolonged intervals risk extended periods of suboptimal thyroid hormone levels. AACE monitoring deadline. 1
Ensure patients understand that while the active ingredient is identical across brands, formulation differences necessitate medical oversight during any transition. AACE patient‑education point. 2